Research Information System
Turkish Journal of Biochemistry, 2025 (SCI-Expanded)
This study emphasizes the importance of determining the serum levels of pentraxin-3 (PTX3), fibroblast growth factor-2 (FGF2), and tumor necrosis factor-stimulated gene-6 (TNFAIP6) in patients with Crimean-Congo hemorrhagic fever (CCHF). This prospective study involved 30 confirmed CCHF patients and 30 healthy controls. Serum concentrations of PTX3, FGF2, and TNFAIP6 were quantified utilizing a quantitative sandwich ELISA method. CCHF patients exhibited markedly elevated PTX3 levels, reflecting an acute inflammatory response. As a long pentraxin, PTX3 functions as a pattern recognition receptor that activates the complement system to aid in pathogen clearance. Additionally, FGF2 levels were significantly increased, indicating a potential role in repairing endothelial damage. Known for promoting angiogenesis and immune regulation, FGF2 may counteract endothelial dysfunction induced by CCHF. Conversely, TNFAIP6 levels were lower in patients, possibly due to shifts in cytokine activity that suppress its anti-inflammatory and extracellular matrix-regulating effects, potentially leading to greater tissue injury. The dysregulation of PTX3, FGF2, and TNFAIP6 in CCHF patients signifies a disrupted equilibrium in inflammatory and vascular response mechanisms. This triad of biomarkers could serve as a valuable tool for assessing the severity of CCHF and may present therapeutic targets for modulating inflammation and mitigating endothelial damage. Achieving a balance among PTX3, FGF2, and TNFAIP6 could be instrumental in alleviating disease complications, thereby suggesting a potential therapeutic strategy for managing CCHF effectively.